I certainly don't know of any generic drug company's sub $250M enterprise value that have better prospects. As far as branded drug/biotech plays, it would all be speculative. If there's any lesson on MNTA, I think it's that they need a first to market, biogeneric, no potential competition to speak of. Then the cash flow would be insane year after year.
Biotechs with better prospects at an enterprise value of $250M? Which ones?
And let me add biotechs that do not have to raise capital/dilute shareholders.
IMO, if Momenta is able to obtain FDA Approval for Copaxone, its technology has a strong competitive position unless Amphastar is able to get the same approval. There is likely going to be duplicate entrants into almost every generic market however how many have the technology to obtain approval for multiple complex molecules? FDA Approval of Copaxone is key to unlocking value whether or not the patent case is won and I think yesterday's news will result in Management being more realistic in signing a FoB partnership.
Its too bad interest rates weren't higher (2-4%) as Momenta could use the interest on its cash position to fund a quarter plus of spend.
Market Data 
Markets 
AI
